Conference Description:

The wave of breakthrough therapies in drug-based management of obesity has triggered a renaissance in metabolic disorders. As GLP-1 receptor agonists establish a new gold standard in weight-loss and first-in-class therapies demonstrate additional benefit in type 2 diabetes, stakeholders are flooding in to redefine the metabolic landscape.

Uniting industry experts dedicated to accelerating the frontier of disease-modifying therapeutics beyond the current standard of care, the Novel Therapies for Type 2 Diabetes and Obesity Summit is the definitive industry forum sharing cross-industry insight to treat an exponentially growing patient population.

From elucidating body weight set points to establish opportunities for therapeutic intervention, to demonstrating metabolic effect in diabetes to treat interrelated cardiorenal comorbidities, join industry experts including Novo Nordisk, Eli Lilly and Company, Altimmune, Regeneron, Boehringer Ingelheim, Amgen and more to navigate the pathway to regulatory approval for big pharma and smaller biotech.


Tickets: https://go.evvnt.com/1541817-2?pid=154
Prices:
Industry - Conference + Workshop Day: USD 4297.00,
Industry - Conference Only: USD 2999.00,
Vendor - Conference + Workshop Day: USD 5297.00,
Vendor - Conference Only: USD 3799.00

Speakers: Ashish Nimgaonkar, Founder and Chief Executive, Glyscend Therapeutics, Jacob Jeppesen, Vice President, Novo Nordisk, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, Jyothis George, Medical Vice President, Global and US Therapeutic Area Head, Cardiovascular and Metabolism, Amgen, Mark Fineman, Chief Development Officer, Glyscend Therapeutics, Mathijs Bunck, Head of Clinical Research, Next Generation Incretins, Eli Lilly and Company, Miriam Kidron,?? Chief Scientific Officer, Oramed Pharmaceuticals, Murielle Veniant-Ellison, Scientific Vice President, Amgen, Nancy Briefs President and Chief Executive Officer AltrixBio, Peter de Haan, Chief Scientific Officer and Co-Founder, Amarna Therapeutics, Randy Seeley, Henry King Ransom Professor of Surgery, University of Michigan, Robert Augustin, Associate Director, Strategic Partnering Cardiometabolism, Boehringer Ingelheim, Robert Pordy, Vice President, Cardiovascular and Metabolism Therapeutics, Regeneron, Sarah Browne, Senior Director, Clinical Development, Altimmune, Siddique Abbasi, Executive Medical Director and Global Development Lead, Amgen, Søren Brunak, Research Director, Disease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research Copenhagen University, Steve Faraci, Chief Scientific Officer, Cyta Therapeutics, Tien Lee, Chief Executive Officer, Officer Aardvark Therapeutics, Uli Stilz, Vice President, Novo Nordisk

Time: 09:00 to 15:30